Conditions: Hematological Malignancies
Keywords: Selinexor KPT-330 Multiple Myeloma non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Waldenström's macroglobulinemia Peripheral T-Cell Lymphoma Cutaneous T-Cell Lymphoma Chronic Myelocytic Leukemia Acute Lymphoblastic Leukemia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 286
Healthy volunteers: no

Brief summary:
The purpose of this research study is to find out more information relating to the highest dose of KCP-330 that can be given safely and side effects it may cause, to examine how the body affects KCP-330 concentrations in the blood (pharmacokinetics or PK), to examine the effects of KCP-330 on the body (pharmacodynamics or PDn) and to obtain information on its effectiveness in treating cancer.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: KPT-330
Intervention descriptions: intervention 1: None

Protocol document: